Book contents
- Frontmatter
- Contents
- CONTRIBUTORS
- PREFACE
- Chap 1 OVERVIEW OF SOFT TISSUE TUMORS
- Chap 2 RADIOLOGIC EVALUATION OF SOFT TISSUE TUMORS
- Chap 3 IMMUNOHISTOCHEMISTRY OF SOFT TISSUE TUMORS
- Chap 4 GENETICS OF SOFT TISSUE TUMORS
- Chap 5 MOLECULAR GENETICS OF SOFT TISSUE TUMORS
- Chap 6 FIBROBLAST BIOLOGY, FASCIITIS, RETROPERITONEAL FIBROSIS, AND KELOIDS
- Chap 7 FIBROMAS AND BENIGN FIBROUS HISTIOCYTOMAS
- Chap 8 FIBROMATOSES
- Chap 9 BENIGN FIBROBLASTIC AND MYOFIBROBLASTIC PROLIFERATIONS IN CHILDREN
- Chap 10 CHILDHOOD FIBROBLASTIC AND MYOFIBROBLASTIC PROLIFERATIONS OF VARIABLE BIOLOGIC POTENTIAL
- Chap 11 MYXOMAS AND OSSIFYING FIBROMYXOID TUMOR
- Chap 12 SOLITARY FIBROUS TUMOR, HEMANGIOPERICYTOMA, AND RELATED TUMORS
- Chap 13 FIBROBLASTIC AND MYOFIBROBLASTIC NEOPLASMS WITH MALIGNANT POTENTIAL
- Chap 14 LIPOMA VARIANTS AND CONDITIONS SIMULATING LIPOMATOUS TUMORS
- Chap 15 ATYPICAL LIPOMATOUS TUMOR AND LIPOSARCOMAS
- Chap 16 SMOOTH MUSCLE TUMORS
- Chap 17 GASTROINTESTINAL STROMAL TUMOR
- Chap 18 STROMAL TUMORS AND TUMOR-LIKE LESIONS OF THE FEMALE GENITAL TRACT
- Chap 19 ANGIOMYOLIPOMA AND RELATED TUMORS (PERIVASCULAR EPITHELIOID CELL TUMORS)
- Chap 20 RHABDOMYOMAS AND RHABDOMYOSARCOMAS
- Chap 21 HEMANGIOMAS, LYMPHANGIOMAS, AND REACTIVE VASCULAR PROLIFERATIONS
- Chap 22 HEMANGIOENDOTHELIOMAS, ANGIOSARCOMAS, AND KAPOSI'S SARCOMA
- Chap 23 GLOMUS TUMOR, SINONASAL HEMANGIOPERICYTOMA, AND MYOPERICYTOMA
- Chap 24 NERVE SHEATH TUMORS
- Chap 25 NEUROECTODERMAL TUMORS: MELANOCYTIC, GLIAL, AND MENINGEAL NEOPLASMS
- Chap 26 PARAGANGLIOMAS
- Chap 27 PRIMARY SOFT TISSUE TUMORS WITH EPITHELIAL DIFFERENTIATION
- Chap 28 MALIGNANT MESOTHELIOMA AND OTHER MESOTHELIAL PROLIFERATIONS
- Chap 29 MERKEL CELL CARCINOMA AND METASTATIC AND SARCOMATOID CARCINOMAS INVOLVING SOFT TISSUE
- Chap 30 CARTILAGE- AND BONE-FORMING TUMORS AND TUMOR-LIKE LESIONS
- Chap 31 SMALL ROUND CELL TUMORS
- Chap 32 ALVEOLAR SOFT PART SARCOMA
- Chap 33 PATHOLOGY OF SYNOVIA AND TENDONS
- Chap 34 MISCELLANEOUS TUMOR-LIKE LESIONS, AND HISTIOCYTIC AND FOREIGN BODY REACTIONS
- Chap 35 LYMPHOID, MYELOID, HISTIOCYTIC, AND DENDRITIC CELL PROLIFERATIONS IN SOFT TISSUES
- Chap 36 CYTOLOGY OF SOFT TISSUE LESIONS
- Chap 37 SURGICAL MANAGEMENT OF SOFT TISSUE SARCOMA: HISTOLOGIC TYPE AND GRADE GUIDE SURGICAL PLANNING AND INTEGRATION OF MULTIMODALITY THERAPY
- Chap 38 MEDICAL ONCOLOGY OF SOFT TISSUE SARCOMAS
- Index
- References
Chap 3 - IMMUNOHISTOCHEMISTRY OF SOFT TISSUE TUMORS
Published online by Cambridge University Press: 01 March 2011
- Frontmatter
- Contents
- CONTRIBUTORS
- PREFACE
- Chap 1 OVERVIEW OF SOFT TISSUE TUMORS
- Chap 2 RADIOLOGIC EVALUATION OF SOFT TISSUE TUMORS
- Chap 3 IMMUNOHISTOCHEMISTRY OF SOFT TISSUE TUMORS
- Chap 4 GENETICS OF SOFT TISSUE TUMORS
- Chap 5 MOLECULAR GENETICS OF SOFT TISSUE TUMORS
- Chap 6 FIBROBLAST BIOLOGY, FASCIITIS, RETROPERITONEAL FIBROSIS, AND KELOIDS
- Chap 7 FIBROMAS AND BENIGN FIBROUS HISTIOCYTOMAS
- Chap 8 FIBROMATOSES
- Chap 9 BENIGN FIBROBLASTIC AND MYOFIBROBLASTIC PROLIFERATIONS IN CHILDREN
- Chap 10 CHILDHOOD FIBROBLASTIC AND MYOFIBROBLASTIC PROLIFERATIONS OF VARIABLE BIOLOGIC POTENTIAL
- Chap 11 MYXOMAS AND OSSIFYING FIBROMYXOID TUMOR
- Chap 12 SOLITARY FIBROUS TUMOR, HEMANGIOPERICYTOMA, AND RELATED TUMORS
- Chap 13 FIBROBLASTIC AND MYOFIBROBLASTIC NEOPLASMS WITH MALIGNANT POTENTIAL
- Chap 14 LIPOMA VARIANTS AND CONDITIONS SIMULATING LIPOMATOUS TUMORS
- Chap 15 ATYPICAL LIPOMATOUS TUMOR AND LIPOSARCOMAS
- Chap 16 SMOOTH MUSCLE TUMORS
- Chap 17 GASTROINTESTINAL STROMAL TUMOR
- Chap 18 STROMAL TUMORS AND TUMOR-LIKE LESIONS OF THE FEMALE GENITAL TRACT
- Chap 19 ANGIOMYOLIPOMA AND RELATED TUMORS (PERIVASCULAR EPITHELIOID CELL TUMORS)
- Chap 20 RHABDOMYOMAS AND RHABDOMYOSARCOMAS
- Chap 21 HEMANGIOMAS, LYMPHANGIOMAS, AND REACTIVE VASCULAR PROLIFERATIONS
- Chap 22 HEMANGIOENDOTHELIOMAS, ANGIOSARCOMAS, AND KAPOSI'S SARCOMA
- Chap 23 GLOMUS TUMOR, SINONASAL HEMANGIOPERICYTOMA, AND MYOPERICYTOMA
- Chap 24 NERVE SHEATH TUMORS
- Chap 25 NEUROECTODERMAL TUMORS: MELANOCYTIC, GLIAL, AND MENINGEAL NEOPLASMS
- Chap 26 PARAGANGLIOMAS
- Chap 27 PRIMARY SOFT TISSUE TUMORS WITH EPITHELIAL DIFFERENTIATION
- Chap 28 MALIGNANT MESOTHELIOMA AND OTHER MESOTHELIAL PROLIFERATIONS
- Chap 29 MERKEL CELL CARCINOMA AND METASTATIC AND SARCOMATOID CARCINOMAS INVOLVING SOFT TISSUE
- Chap 30 CARTILAGE- AND BONE-FORMING TUMORS AND TUMOR-LIKE LESIONS
- Chap 31 SMALL ROUND CELL TUMORS
- Chap 32 ALVEOLAR SOFT PART SARCOMA
- Chap 33 PATHOLOGY OF SYNOVIA AND TENDONS
- Chap 34 MISCELLANEOUS TUMOR-LIKE LESIONS, AND HISTIOCYTIC AND FOREIGN BODY REACTIONS
- Chap 35 LYMPHOID, MYELOID, HISTIOCYTIC, AND DENDRITIC CELL PROLIFERATIONS IN SOFT TISSUES
- Chap 36 CYTOLOGY OF SOFT TISSUE LESIONS
- Chap 37 SURGICAL MANAGEMENT OF SOFT TISSUE SARCOMA: HISTOLOGIC TYPE AND GRADE GUIDE SURGICAL PLANNING AND INTEGRATION OF MULTIMODALITY THERAPY
- Chap 38 MEDICAL ONCOLOGY OF SOFT TISSUE SARCOMAS
- Index
- References
Summary
This chapter outlines the biologic background and the tissue distribution of the most significant immunohistochemical markers for soft tissue tumors. Tumor type-specific applications are detailed in Chapters 6 to 35. Markers for mesothelioma are presented in Chapter 28, those for metastatic carcinomas in Chapter 29, and those for lymphohematopoietic tumors in Chapter 35. Some very specialized “one-tumor markers” are discussed only with their specific applications in tumor-specific Chapters 6 to 35. Several reviews are suggested for further reading.
The most important cell type markers are grouped under subheadings of endothelial and multispecific, muscle cell, neural and neuroendocrine, melanoma and histiocytic markers, keratins, other epithelial and mesothelial markers, other cell type markers, and cell cycle markers. These markers and their main diagnostic targets have been listed in Table 3.1. Conversely, several previously used immunohistochemical markers have proved either diagnostically nonspecific or impractical to use and have been replaced by better markers (Table 3.2).
Immunohistochemistry is the most practical way to evaluate the presence of certain protein and carbohydrate epitopes on tissue sections. Evaluation of cell- or tumor-type specific or cell cycle related markers is often highly significant, both diagnostically and differentially, although very few markers are totally specific for one tumor type, and no cell cycle marker can separate benign and malignant tumors.
Detailed knowledge of antigen expression in normal tissues and different tumors is also important for understanding the diagnostic potential of various markers. There are estimated 30,000 to 50,000 genes, some of which undiscovered as of yet.
- Type
- Chapter
- Information
- Modern Soft Tissue PathologyTumors and Non-Neoplastic Conditions, pp. 44 - 104Publisher: Cambridge University PressPrint publication year: 2010
References
- 4
- Cited by